Mayo Clinic scientists have identified a molecular 'switch' in lung cells that decides whether cells focus on repairing tissue or fighting infection. The discovery in alveolar type 2 (AT2) cells could lead to treatments for chronic lung diseases like COPD and pulmonary fibrosis. Targeting this switch may restore lung repair, reduce scarring, and improve recovery after infections.